Johnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV treatment for patients with no darunavir resistance-associated mutations. The drug is taken with ritonavir and in combination with other HIV medicines. Prezista is co-developed with Janssen Therapeutics, a division of JNJ owned Janssen Pharmaceutical.